eluting stents



Eluting stents
介入治疗目前面临着重大挑战，是治疗后血管再狭窄问题，在全球所有的血管成形术或支架放置病例中，约有15％－30％发生再狭窄，复杂病例可高达50％的再狭窄率。新型药物支架则在普通的金属支架上涂布一层药物，使再狭窄的可能性大幅降低至10％以内，因此被称为是“冠心病治疗史上的一次革命”。药物涂层支架为解决支架术后再狭窄提供了一种新的预防途径，是目前研究的热点之一。主要有药物包被支架（ coating stent ）与药物洗脱支架（ eluting stent ）。目前国际上的一些大规模临床研究均证实药物释放支架置入后，再狭窄率极低，令人信服地证明了在降低再狭窄率方面的安全性和有效性。为此CMBI特准备了关于Eluting stents的特别报道，供实践参考,更多文献,请用相关关键词通过CMBI文献查询获取。
Drug-eluting stents have made brachytherapy obsolete Sirolimus-eluting stents for the prevention of restenosis in a worst-case scenario of diffuse and recurrent in-stent restenosis Drug-eluting stents caution and concerns for long-term outcome Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents Tumor Necrosis Factor-α Antibody Eluting Stents Reduce Vascular Smooth Muscle Cell Proliferation Thrombosis and drug-eluting stents The impact of Sirolimus Eluting stents in interventional cardiology The future of CART in the era of drug eluting stents The Evidence for Drug-Eluting Stents Sustained reduction of in-stent neointimal growth with the use of a novel systemic nanoparticle paclitaxel Successful management of osteal perforation of left anterior descending artery with coated stent Randomized Study to Assess the Effectiveness of slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions Sirolimus-eluting stents for the treatment of obstructive superficial femoral artery disease Sirolimus-eluting stent for the treatment of in-stent restenosis RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent Pathology and implications for the development of drug eluting stents Vascular Responses at Proximal and Distal Edges of paclitaxel-eluting stents-serial intravascular ultrasound analysis New frontiers in cardiology-drug-eluting stents-2 New frontiers in cardiology-drug-eluting stents-1 New approaches to preventing restenosis multicenter Randomized Study With the Sirolimus-Eluting Bx Velocity Balloon-Expandable Stent Molecular Mechanisms of In-Stent Restenosis and Approach to Therapy with Eluting Stents Methotrexate eluting stents Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent In-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer Persistent Inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation-long-term (up to 2 years) In vitro evaluation of vascular endothelial growth factor (VEGF)-eluting stents In vitro evaluation of c7E3-Fab (ReoPro) eluting polymer-coated coronary stents Heparin-coated Wiktor stents in human coronary arteries Drug-eluting stents-new era and new concerns Drug-eluting stents-cost versus clinical benefit Drug-eluting and coated stents Drug eluting stents-are human and animal studies comparable.htm Drug eluting stents-maximising benefit and minimising cost Coated ureteral metallic stents Coated Stents for the Prevention of Restenosis-2 Coated Stents for the Prevention of Restenosis-1 Chronic arterial responses to polymer-controlled paclitaxel-eluting stents 7-hexanoyltaxol-eluting stent for prevention of neointimal growth Are drug-eluting stents a panacea for patients with coronary heart disease A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents Treatment of Left Anterior Descending Coronary Artery Disease With Sirolimus-Eluting Stents Local Gene Transfer of phVEGF-2 Plasmid by Gene-Eluting Stents Intraprocedural Stent Thrombosis During Implantation of Sirolimus-Eluting Stents Drug-Eluting Stents Anticipated Impact of Drug-Eluting Stents on Referral Patterns for Coronary Artery Bypass Graft Surgery Impact of Sirolimus-Eluting Stents on Outcome in Diabetic Patients Randomized Study to Evaluate Sirolimus-Eluting Stents Implanted at Coronary Bifurcation Lesions Vascular Responses at Proximal and Distal Edges of Paclitaxel-Eluting Stents Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the Real World Drug-Eluting Stents Drug-Eluting Stents Show Promise Chronic Arterial Responses to Polymer-Controlled Paclitaxel-Eluting Stents Bringing Reality to Drug-Eluting Stents In vitro evaluation of vascular endothelial growth factor (VEGF)-eluting stents Usefulness of shear stress pattern in predicting neointima distribution in sirolimus-eluting stents in coronary arteries Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery Drug-Eluting Stents And Glycoprotein Iib-Iiia Inhibitors-Combination Therapy For The Future Sirolimus-Eluting Stents Versus Standard Stents In Patients With Stenosis In-Native Coronary Artery New Frontiers in Cardiology-Drug-Eluting Stents-Part I New Frontiers in Cardiology-Drug-Eluting Stents-Part II New Frontiers in Cardiology-Drug-Eluting Stents Implantation of Sirolimus-Eluting Stents in Human Coronary Arteries Drug-eluting stents in vascular intervention Drug eluting stents- are human and animal studies comparable IN-STENT STENOSIS-PATHOLOGY AND IMPLICATIONS FOR THE DEVELOPMENT OF DRUG ELUTING STENTS Drug eluting stents-maximising benefit and minimising cost Drug eluting stents-are human and animal studies comparable Perspectives of Drug-Eluting Stents-The Next Revolution Drug-Eluting Stents in Preclinical Studies Drug-eluting stents for the prevention of restenosis Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting Stents One-Year Angiographic and Intravascular Ultrasound Follow-Up

Last Modified: 2004-12-26